Phase I of the Clinical trial

In phase I clinical trial, everything is public. Most of them know that clinical trial starts at phase I. The process of the clinical trial is not an open book to everybody, the process of phase I in the clinical trial is still left uncleared. The main objective of the phase is to conclude the tolerated dosage of particular medicine. The traditional methods like 1-in-3” or 3+3 design proves to be unreliable unpredictable and likely to choose a lower therapeutically ineffective dose.  

The adaptive phase I trial in the medical trial identifies the minimum effective dose and maximum tolerable dose to process ahead with the further phases of the clinical trial. Implementation of the new techniques like continuous reassessment methods helps in reducing the sample size and overall toxicity in the medical trial. This helps in improving the accuracy and precision of the maximum tolerable dose predictions. Continuous reassessment methods lies the focus on safety, in evaluating maximum tolerant dosage.